STUDY DESIGN FOR CLINICAL EVALUATION OF PHENOTHIAZINE DERIVATIVES
Abstract
A short clinical screen was devised for quickly assessing the value of new phenothiazine compounds in treating schizophrenia. The 3-month controlled trial utilizing chlorpromazine as the standard, embraces only patients stubbornly resistant to treatment, and employs a special rating scale to differentiate among the various common drug actions. Carphenazine maleate was the first drug tested. It was found to be superior to chlorpromazine in ability to influence mood, physical and mental activity, degree of hostility and tension. It is recommended for use in chronic schizophrenia when other therapies fail.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).